AbCellera has entered a collaboration with Merck to generate antibodies against an undisclosed disease target.   AbCellera will apply its high-throughput antibody discovery platform to identify antibodies that specifically modulate target function. Merck has the option to develop antibody candidates identified through the collaboration for specified therapeutic applications. Financial terms were not disclosed.   “Our platform has the potential to generate functional antibodies against extrem...